certolizumab pegol
Selected indexed studies
- Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis. (BioDrugs, 2020) [PMID:32207094]
- Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial. (Ann Rheum Dis, 2025) [PMID:40483169]
- Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy. (Skin Therapy Lett, 2021) [PMID:33769772]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Certolizumab pegol for induction of remission in Crohn's disease. (2019) pubmed
- Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis. (2020) pubmed
- Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial. (2025) pubmed
- Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy. (2021) pubmed
- Certolizumab pegol. (2010) pubmed
- Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. (2023) pubmed
- Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics and treatment. (2024) pubmed
- Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. (2020) pubmed
- Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. (2017) pubmed
- Certolizumab pegol: in Crohn's disease. (2007) pubmed